HealthcareInnovation

CHICAGO – A groundbreaking clinical trial presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 has demonstrated that patients with advanced solid tumors experience significantly improved survival outcomes when treatment is tailored using information from both tissue and liquid biopsies. The findings from the phase II, multicenter ROME trial could redefine the approach to precision oncology and patient care.